Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
about
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsSecond-Line Therapy for Advanced NSCLCCIViC databaseMolecular pathology of non-small cell lung cancer: a practical guide.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisClinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerClinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.Identification of ALK gene alterations in urothelial carcinoma.Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerA case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangementsFDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.ALK in lung cancer: past, present, and future.Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patientsBuyer beware: understanding the assumptions behind health economic assessments in personalized cancer care.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondRelationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung CancerBiomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASPredictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexedPROFILE 1014: lessons for the new era of lung cancer clinical research.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyPemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerIs there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung CancerClinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.First-line treatment of advanced ALK-positive non-small-cell lung cancer.Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.Treating ALK-positive lung cancer--early successes and future challenges.The place of pemetrexed in the management of non-small-cell lung cancer patients.Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
P2860
Q26795555-7DA5B396-6507-4C3B-944C-B5015B80C159Q26820845-E836E677-0584-4A2E-A765-79109B654C92Q27002398-B59832FE-2E56-4A03-AF01-1C07635C3463Q27612411-D53C2DBF-CD4C-4C11-8E7E-FCD1489E7F03Q27690919-24C7BD6C-4155-4C9C-9303-ACACFF72C3BEQ27851671-3E450BC3-877F-4C0C-AA4D-4DCB90885D57Q31167585-CFEE7C61-FCEB-49B7-9FCD-DD25473EFB36Q33429242-20B68EC7-0542-4556-A9B3-E37212C5F3F7Q33844713-FD47AB15-5BE3-4847-9B54-D2BED193C037Q33989002-5B7E8346-BDEC-46F1-BC95-F8859F9FD454Q34019159-C003B3D6-55C2-43F0-AEE9-D55DE1C2154EQ34145016-B20CAA6F-DFA1-4AD0-AEFD-D27B64C3B578Q34359341-2ED89917-804E-4E2F-95F3-DF130E89E7A1Q34402260-1D7AFC9B-D514-4040-98F5-DDAD2C720909Q34566472-B82CCD15-F65D-444E-9A07-C52278F97985Q34814396-FE2AC25C-C4B8-47B2-99AA-8995C86B6973Q35136424-3EB53F6A-2942-4BA5-9CD3-62D91375FE39Q35596686-5F196835-6E3E-4111-BC89-4ECF33C77B1EQ35812568-69C2FE08-5248-4C4A-BBCF-BDFFD056E0E6Q36040606-9E41CFDB-D410-494C-8F61-7F31FB296379Q36070007-C41CB7D5-6C57-4BAF-A361-8237FAF9595AQ36241808-086B9B27-C931-4B16-AB82-D9E7E8B3C6D5Q36250691-3A253FE3-61C0-47DF-A321-2DBD0335EE37Q36405628-C14D4F32-AA35-48ED-B949-C13C1FD74BBBQ36474900-7CCF712C-AEFC-4D27-935D-4B2F0DEF89F1Q37045504-3327C92B-80EE-4E4F-A4FC-EBB8F836D44DQ37060397-0D5350D1-C21E-443E-9FC8-9C3B9CF60DD7Q37298872-B82B1072-955A-4245-B1C1-11BD56AFA401Q37349315-A8D0B46C-9D48-470B-9467-C3010FE6F257Q37373037-E28C954B-AD9D-4E5B-89B7-A43192ED0D28Q37431563-6CBDABA3-31DE-4E99-8203-2E33268FC523Q37566842-E84FEFB4-FEE5-46C6-ACB9-47975334E0B7Q37597299-4EB591CA-18F6-40BF-A919-B37113864CB3Q37606591-0A7E3D10-8598-4AA9-BD07-1B8AD9B04DBDQ37982440-0FF02F1A-9494-4FFA-AB69-12351B067F37Q37996424-FBBE34C9-F5F5-4833-8D4D-6EA6EF738D58Q37999657-77633F6A-46BF-49E5-B4A3-84CC765B5ED0Q38087999-E7C021E8-21D3-4C01-9B5D-68850881AA97Q38096472-D11E462D-4005-4C11-B016-ACF521900A60Q38101614-8E26FCC7-0282-4595-AABC-35B7016923B9
P2860
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@ast
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@en
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@nl
type
label
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@ast
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@en
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@nl
prefLabel
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@ast
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@en
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@nl
P2093
P3181
P1476
Anaplastic lymphoma kinase tra ...... th non-small cell lung cancer.
@en
P2093
Dae Seog Heo
Dong-Wan Kim
Doo Hyun Chung
Jeong-Ok Lee
Se-Hoon Lee
Seok-Chul Yang
Soyeon Kim
Tae Min Kim
Woo-Ho Kim
Yoon-Kyung Jeon
P304
P3181
P356
10.1097/JTO.0B013E3182208FC2
P577
2011-09-01T00:00:00Z